Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Gastroesophageal and Colorectal Cancers | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Gastroesophageal and Colorectal Cancers

2:00:22
 
Share
 

Manage episode 422902037 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring perspectives from Ms Deanna A Griffie, Ms Caroline Kuhlman, Dr Manish A Shah and Dr John Strickler, including the following topics:

  • Introduction (0:00)
  • The Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Nonmetastatic Gastroesophageal Cancers (11:30)
  • The Potential Role of Immune Checkpoint Inhibitors (ICIs) as Neoadjuvant Therapy for Patients with Gastric/Gastroesophageal Junction Cancer (20:53)
  • First-Line Therapy for Metastatic Gastroesophageal Cancers (36:16)
  • The Potential Role of Therapy Targeting Claudin 18.2 for Gastroesophageal Cancers (42:16)
  • Targeted Therapies for HER2-Positive Gastroesophageal Cancers (51:42)
  • Selection of Appropriate Candidates with Localized Colorectal Cancer (CRC) for Adjuvant Therapy (1:14:24)
  • The Current Role of ICIs in the Treatment of Metastatic CRC (mCRC) (1:23:32)
  • Tolerability and Other Practical Considerations with ICIs (1:25:57)
  • The Role of TAS-102/Bevacizumab in the Management of Relapsed/Refractory (R/R) mCRC (1:36:14)
  • The Potential Role of KRAS-Targeted Therapy in the Management of mCRC (1:44:36)

NCPD information and select publications

  continue reading

1376 episodes

Artwork
iconShare
 
Manage episode 422902037 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring perspectives from Ms Deanna A Griffie, Ms Caroline Kuhlman, Dr Manish A Shah and Dr John Strickler, including the following topics:

  • Introduction (0:00)
  • The Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Nonmetastatic Gastroesophageal Cancers (11:30)
  • The Potential Role of Immune Checkpoint Inhibitors (ICIs) as Neoadjuvant Therapy for Patients with Gastric/Gastroesophageal Junction Cancer (20:53)
  • First-Line Therapy for Metastatic Gastroesophageal Cancers (36:16)
  • The Potential Role of Therapy Targeting Claudin 18.2 for Gastroesophageal Cancers (42:16)
  • Targeted Therapies for HER2-Positive Gastroesophageal Cancers (51:42)
  • Selection of Appropriate Candidates with Localized Colorectal Cancer (CRC) for Adjuvant Therapy (1:14:24)
  • The Current Role of ICIs in the Treatment of Metastatic CRC (mCRC) (1:23:32)
  • Tolerability and Other Practical Considerations with ICIs (1:25:57)
  • The Role of TAS-102/Bevacizumab in the Management of Relapsed/Refractory (R/R) mCRC (1:36:14)
  • The Potential Role of KRAS-Targeted Therapy in the Management of mCRC (1:44:36)

NCPD information and select publications

  continue reading

1376 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide